Abstract

It is hypothesized that a fundamental function of sleep is to restore an individual’s day-to-day ability to learn and to constantly adapt to a changing environment through brain plasticity. Brain-derived neurotrophic factor (BDNF) is among the key regulators that shape brain plasticity. However, advancing age and carrying the BDNF Met allele were both identified as factors that potentially reduce BDNF secretion, brain plasticity, and memory. Here, we investigated the moderating role of BDNF polymorphism on sleep and next-morning learning ability in 107 nondemented individuals who were between 55 and 84 years of age. All subjects were tested with 1 night of in-laboratory polysomnography followed by a cognitive evaluation the next morning. We found that in subjects carrying the BDNF Val66Val polymorphism, consolidated sleep was associated with significantly better performance on hippocampus-dependent episodic memory.
tasks the next morning ($\beta$-values from 0.290 to 0.434, $p \leq 0.01$). In subjects carrying at least one copy of the $BDNF$ Met allele, a more consolidated sleep was not associated with better memory performance in most memory tests ($\beta$-values from $-0.309$ to $-0.392$, $p$ values from 0.06 to 0.15). Strikingly, increased sleep consolidation was associated with poorer performance in learning a short story presented verbally in Met allele carriers ($\beta = -0.585$, $p = 0.005$). This study provides new evidence regarding the interacting roles of consolidated sleep and $BDNF$ polymorphism in the ability to learn and stresses the importance of considering $BDNF$ polymorphism when studying how sleep affects cognition.

**Keywords**

aging; brain derived neurotrophic factor; cognition; memory; sleep; slow-wave sleep

---

**Introduction**

There is strong evidence supporting the fundamental role of sleep in brain plasticity, memory, and learning (Diekelmann and Born, 2010). Sleep facilitates the consolidation of new information or abilities learned the previous day (Walker et al., 2002; Peigneux et al., 2004). The characteristics of sleep also predict the ability to learn new material after the sleep episode (Mander et al., 2011; Lafortune et al., 2014), and total sleep deprivation impedes subsequent encoding in episodic memory (Drummond et al., 2000; Yoo et al., 2007). The synaptic homeostasis hypothesis suggests that in response to learning, synaptic potentiation increases in the cortex and the hippocampus during wakefulness, which eventually saturates the ability to learn (Tononi and Cirelli, 2014). The same authors proposed that sleep—particularly slow-wave activity (SWA) occurring during non-rapid eye movement (NREM) sleep—restores the ability to learn by depressing synaptic strength. Suppression of SWA before learning was shown to affect hippocampal activity and next-day memory even when total sleep time is not reduced (Van Der Werf et al., 2009, 2011).

Sleep consolidation is another sleep characteristic that plays a major role in memory and synaptic plasticity. Rodent studies suggest that sleep fragmentation, independently of sleep duration, impairs long-term potentiation and the ability to learn (Tartar et al., 2006; Wallace et al., 2015). Moreover, a minimal unit of uninterrupted sleep, or sleep bout, is necessary to improve next-day learning (Rolls et al., 2011).

The availability of brain-derived neurotrophic factor (BDNF), a secretory peptide, is crucial for synaptic plasticity (Kang and Schuman, 1995). BDNF is released in response to neural activity and plays a key role in activity-dependent synaptic strengthening (Korte et al., 1995). One factor that intrinsically modulates the availability of BDNF in the human brain is the rs6265 single nucleotide polymorphism in the $BDNF$ gene. In Caucasians, 25–35% of the population carries a valine (Val) to methionine (Met) substitution at codon 66 (referred to as Met carriers) and has reduced activity-dependent BDNF secretion compared with homozygous $BDNF$ Val allele carriers (referred to as Val/Val carriers; Egan et al., 2003). Several studies have linked reduced BDNF secretion in Met carriers with lower synaptic plasticity and poorer memory (Baj et al., 2013), although significant inconsistencies exist.

*J Neurosci*. Author manuscript; available in PMC 2018 February 13.
Mandelman and Grigorenko, 2012). In comparison with Val/Val carriers, it was suggested that Met carriers experience growing impairment on memory tasks as they age (Kennedy et al., 2015), making the aging population particularly appealing to understanding how the BDNF Met allele affects memory.

It is unknown whether sleep and BDNF polymorphism interact to predict the ability to encode new episodic memory the next morning. The present study aims to ascertain whether BDNF polymorphism moderates the association between sleep (more specifically, NREM SWA, and sleep consolidation) and performance on subsequent episodic declarative memory tasks. Given that sleep plays a crucial role in memory and synaptic plasticity, and that the BDNF Met allele was shown to reduce brain plasticity, we hypothesized that the positive effect of sleep on new learning the next morning would be significantly reduced among Met carriers compared with Val/Val carriers.

Materials and Methods

Subjects

A total of 107 middle-aged and older nondemented adults (88 men and 19 women) between 55 and 84 years of age took part in this study. Seventy-nine subjects carried the wild-type Val66Val polymorphism (Val/Val carriers), while 28 subjects carried at least one copy of the Met allele (Met carriers), representing 26.2% of our study sample (Table 1, subject characteristics). Among the Met carriers, 27 participants carried one BDNF Met allele and one participant carried the BDNF Met66Met polymorphism. This study was part of a longitudinal study on aging, cognition, and obstructive sleep apnea. Subjects were recruited from the waiting list of a sleep apnea clinic at Hôpital du Sacré-Coeur de Montréal and through the media. Twenty-four of the 79 Val/Val subjects (30%) were recruited from the waiting list of the sleep apnea clinic versus 9 of the 28 Met carriers (32%). No significant difference was found between the two groups in the proportion of participants recruited through the sleep apnea clinic versus through the media (χ² = 0.03, p = 0.86). Our exclusion criteria were as follows: diagnosis of dementia based on a medical examination and according to established criteria (American Psychiatric Association, 2013); a score of <24 on the Mini Mental State Examination (Folstein et al., 1975); a score of <21 on the Montreal Cognitive Assessment (Nasreddine et al., 2005); diagnosis of a sleep disorder other than obstructive sleep apnea (e.g., narcolepsy, insomnia, rapid-eye movement (REM) sleep behavior disorder, restless leg syndrome); morbid obesity, defined as a body mass index of >40 kg/m²; a history of head injury, stroke, encephalopathy, psychiatric or neurological disease, chronic obstructive pulmonary disease, use of psychotropic medications (including drugs or alcohol abuse) that can influence sleep or cognition; use of continuous positive air pressure; and the presence of electroencephalographic anomalies suggestive of epilepsy. All participants gave written consent to participate in the study, and the hospital ethics committee approved the study. Subjects were compensated financially for participating.

Procedure

The protocol included a blood sample for genetic profiling, brain magnetic resonance imaging (MRI) acquisition to control for hippocampal volume, and an in-laboratory
polysomnography (PSG) followed by neuropsychological assessment the next morning. Participants’ size and weight were measured in the laboratory. Vascular risk factors were assessed using the Vascular Burden Index, a questionnaire that screens for hypertension, hypotension, hypercholesterolemia/dyslipidemia, coronary disease (angina pectoris, myocardial infarction, coronary artery bypass), transient ischemic attacks, diabetes, arrhythmias, and carotid stenosis based on previous medical observations (Villeneuve et al., 2009). All subjects filled out the following questionnaires to ensure that groups were not different in terms of mood and sleep complaints: the Beck Depression Inventory, second edition (Beck et al., 1996); the Beck Anxiety Inventory (Beck and Steer, 1993); the Pittsburgh Sleep Quality Index (Buysse et al., 1989); the Epworth Sleepiness Scale (Johns, 1991); and the Insomnia Severity Index (Bastien et al., 2001). Finally, all subjects filled out questionnaires on memory complaints (Self-Evaluation Questionnaire; Van Der Linden et al., 1989; Clément et al., 2008) and subjective cognitive complaints (Cognitive Failure Questionnaire; Broadbent et al., 1982).

**Polysomnographic recording**

Subjects were tested with 1 night of in-laboratory PSG recording that began between 9:22 P.M. and 12:18 A.M. and ended between 5:40 and 8:36 A.M. the next morning, depending on each participant’s regular sleep schedule. Sleep was recorded using a 17-channel montage (Fz, F3, F4, F7, F8, Cz, C3, C4, T7, T8, Pz, P3, P4, P7, P8, O1, and O2) using the international 10–20 system with a linked mastoid reference. A Grass Technologies Model 15A54 Polygraph (amplifier gain, 7.5 μV/mm; bandpass filter, 0.3–100 Hz) was used for recording, and all signals were digitized at a sampling rate of 256 Hz using commercial software (Harmonie, Natus). PSG included an electrooculogram, a submental electromyogram, and an electrocardiogram. Periodic leg movements were measured using an electromyogram of the bilateral anterior tibialis muscles. Thoracoabdominal strain gauges, oronasal thermistors, and oronasal cannula were used to monitor respiration, and a transcutaneous finger pulse oximeter was used to measure oxygen saturation.

**Neuropsychological assessment**

All neuropsychological assessments were performed in the morning following the PSG recording and started at ~9:00 A.M. They included the following two episodic memory tasks: the Rey Auditory Verbal Learning Test (RA VLT; Rey, 1941); and the Logical Memory subtest of the Wechsler Memory Scale, third edition (Wechsler, 1997).

In the RAVLT, participants heard the same list of 15 common words five times. Each time, immediately after listening to the list, the subjects were asked to repeat as many words as they could recall. A second list of 15 words was then presented, followed by an immediate recall of the first list of words. A fixed battery of other cognitive tests that did not involve learning verbal material was administered for ~20 min after the immediate recall. After this period, participants were asked to recall the first list of words they learned. In the present study, we used the total number of correctly recalled words for the five learning trials as well as the number of correctly recalled words for delayed recall.
We also used the immediate and 30 min delayed recalls of Story A, a short story presented verbally to participants, which is part of the Logical Memory subtest. We administered a modified version of the Logical Memory subtest in which Story A is presented, followed by an immediate recall and an immediate recognition task. After a 30 min period during which nonverbal tests were presented, participants were asked to recall Story A. In this modified version, Story B was not presented to reduce interference. Scores for immediate and delayed recalls were calculated separately by summing the number of correct story items reported by the participant for each recall.

Other neuropsychological tests administered were the Continuous Performance Test (Beck et al., 1956), the Digit Span subtest of the Wechsler Adult Intelligence Test, third edition (Wechsler, 1997), semantic and alphabetic fluency (Benton et al., 1994), the Trail Making Test (Reitan, 1958), the Color-Word Interference Test of the Delis-Kaplan Executive Function System (Delis et al., 2001), and the Tower of London Test (Culbertson and Zillmer, 1998). Neuropsychological tests were administered and scored blinded to the BDNF polymorphism group.

**MRI acquisition**

MRI acquisition was performed for 44 Val homozygotes and 16 Met allele carriers; other subjects were excluded from this part of the protocol due to MRI contraindications (i.e., orthopedic materials, pacemakers, or coronary stents) or claustrophobia. We used a Magnetom TRIO 3 tesla MRI scanner (Siemens Healthcare) with a three-dimensional T1-weighted MPRAGE Turbo Flash multiecho system acquired with the following parameters of the Massachusetts General Hospital (Boston, MA): TR, 2530 ms; TE, four echo times: 1.64, 3.50, 5.36, and 7.22 ms; matrix size, 256 × 256; FOV, 256 × 256; voxel size, 1.0 mm isotropic; flip angle, 7°; and 176 sagittal orientations.

**Data analysis**

Sleep—Sleep stages and events were scored according to the American Academy of Sleep Medicine Manual (Iber et al., 2007) by a trained medical electrophysiology technologist (H.B.). Sleep variables were calculated for the nocturnal sleep period (i.e., time from sleep onset through last epoch of sleep). The following variables were derived: total sleep time, sleep efficiency (percentage of time asleep during the sleep period), number of awakenings, and percentage of each sleep stage. We also analyzed the longest sleep bout during the sleep period as a measure of sleep consolidation. All sleep stages were considered in sleep bout measurement, with the exclusion of sleep bouts consisting solely of stage N1 sleep. The end of a sleep bout was determined by the occurrence of an epoch of wake. For the longest sleep bouts, 55.6% included both NREM and REM sleep, whereas 44.4% included only NREM sleep. To derive a single measure of sleep consolidation, a principal component analysis (PCA) with a varimax rotation was performed on the following variables: sleep efficiency, number of awakenings, and longest sleep bout. These three variables were selected because they were highly correlated (absolute r values ranging from 0.28 to 0.47; p values ranging from 0.002 to <0.000001). Only one significant component was obtained with PCA; it explained 58.9% of the variance and was used as the “sleep consolidation index,” with a higher index representing better sleep consolidation. The component matrix showed that the
three sleep variables included in the PCA highly correlated with the component extracted (absolute $r$ values ranging from 0.70 to 0.83).

An apneic episode was defined as a total cessation of airflow lasting ≥10 s. A hypopneic episode was defined as a reduction in airflow of at least 30% from baseline lasting ≥10 s and accompanied by an oxygen desaturation of at least 3% or accompanied by an episode of arousal. The sum of the apnea and hypopnea episodes divided by the number of hours of sleep provides the apnea–hypopnea index.

Spectral analysis for NREM (stages N2 and N3) SWA (0.6–4 Hz) was performed on 5 s artifact-free sections using a fast Fourier transform (cosine tapering) and commercial software (Stellate Systems) to compute SWA (0.6–4 Hz) on F3 electrode. Epochs containing artifacts were considered as missing data to preserve sleep continuity. All-night NREM SWA was calculated for each subject and was averaged on 30 s epochs. Three Val/Val allele carriers and two Met allele carriers were excluded from the SWA analysis because they had significant artifacts on the F3 electrode, impeding spectral analyses.

**BDNF genotyping**—Genomic DNA was extracted from buffy coat using the Qiagen EZ1 DNA kit. Genotype profiling of the *BDNF* rs6265 (Val66Met) polymorphism was conducted through PCR followed by pyro-sequencing. A PCR approach was used for amplification with the following primer pairs: forward biotin, 5′-GGACTCTGGAGAGCGTGAAT-3′, and reverse, 5′-CCGAACCTTCTGGTCTCTATC-3′. Genomic DNA (250–500 ng) was amplified with 10 pM of each primer, 1× PCR buffer kit (Qiagen), 0.4 mM deoxynucleotide (dNTP), 1.0 mM MgCl$_2$, and 0.01 U of Taq polymerase (Qiagen). A Biometra TProfessional Basic thermocycler was used for amplification with the following conditions for 35 cycles: 30 s at 95°C, 30 s at 61.2°C, and 1 min at 72°C. These 35 amplification cycles were preceded by a 2 min hot start at 95°C followed by a final 4 min extension to the last cycle at 72°C. PCR products were visualized on a 1.2% agarose gel. The Val66Met polymorphism was subsequently determined via an established pyrosequencing protocol with oligo sequencing 5′-GCTGACACTTTCGAACA-3′ (Baj et al., 2013). The analyzed sequence was as follows: CA/GTGATAGAA-GAG. BDNF genotypes were validated on a subsample of 45 participants using TaqMan assay number C_11592758_10 on a Viia7 Real-Time Cycler (Life Technologies).

**Apolipoprotein E ε4 allele genotyping**—Apolipoprotein E ε4 allele (APOE4) genotyping was conducted to evaluate the proportion of individuals carrying the APOE4, a well known risk factor for Alzheimer’s disease (Poirier, 2003). This variable contributed to ensure that our two groups were equivalent in the proportion of individuals susceptible to present preclinical dementia. Genomic DNA was extracted from buffy coat using the Qiagen EZ1 DNA Kit. Genotype profiling of ApoE 112/158 single nucleotide polymorphisms (which determine the E2, E3, and E4 isoforms) was performed through PCR followed by pyrosequencing. A PCR approach was used for amplification with the following primer pairs: ApoE 112: forward, 5′-ACGGCTGTCCAAGGAGCTG-3′, and reverse, biotin 5′-CACCTCGCCGCGGTACTG-3′; and ApoE 158: forward, 5′-CTCCCGGATGCGCCGATGAC-3′, and reverse, biotin 5′-CCCCGGCCTGGTACACTG-3′. Genomic DNA (250–500 ng) was amplified with 20 pM each primer, 1× PCR buffer kit

*J Neurosci.* Author manuscript; available in PMC 2018 February 13.
(Qiagen), 0.4 mM dNTP, 1.0 mM MgCl$_2$, DMSO, and 0.01 U of Qiagen Taq polymerase. A Biometra TProfessional Basic Thermocycler was used for amplification with the following conditions for 35 cycles: 30 s at 95°C, 30 s at 58.6°C, or 58.1°C for ApoE 112 or 158 respectively, and 1 min at 72°C. These 35 amplification cycles were preceded by a 2 min hot start at 95°C and were followed by a final 4 min extension to the last cycle at 72°C. PCR products were visualized on a 1.2% agarose gel. The polymorphisms were subsequently determined via an established pyrosequencing protocol with oligo sequencing for ApoE112 (5′-CGGACATGGAGGACG-3′) and ApoE 158 (5′-CGATGACCTGCAGAAG-3′). The analyzed sequence was as follows: TGT/CGCGGCCGCCT for ApoE112 and T/CGCCTG GCAG for ApoE158.

**Hippocampal volume measurement**

Hippocampal volume was measured as a control procedure to ensure that our two groups were equivalent. Using FreeSurfer Image Analysis Suite version 5.3.0. (Laboratory for Computational Neuroimaging, Center for Biomedical Imaging, Charlestown, MA), a volumetric segmentation of all subcortical structures was performed on individual T1-weighted images. This process has been extensively described in previous studies (Fischl et al., 2002, 2004), and the FreeSurfer image analysis suite is documented and available online. Briefly, this volume-based subcortical stream consists of automated steps that include the removal of non-brain tissue, an automated Talairach transformation, and a volumetric segmentation and labeling of subcortical structures. All the individual processed images were visually inspected to assess the quality of the segmentation, and left and right hippocampal volumes were extracted. Hippocampal volume was measured to describe the BDNF polymorphism groups.

**Statistical analyses**

Statistical analyses were conducted using SPSS for Mac version 20.0 (SPSS Science). Differences between BDNF polymorphism groups on demographic, neuropsychological, neuroimaging, and sleep variables were measured using Student’s $t$ tests or $\chi^2$ tests, depending on the type of variable. The hypothesis that the BDNF polymorphism would interact with all-night NREM SWA (0.6–4.0 Hz) and the sleep consolidation index to predict memory performance the next morning was tested using eight hierarchical linear regressions. More specifically, we tested whether BDNF polymorphism is a moderating variable that affects the direction and/or the strength of the relation between independent variables (i.e., NREM SWA and sleep consolidation) and dependent variables (i.e., performance in the memory tests; Baron and Kenny, 1986). Four memory variables were used: for RAVLT, (1) the number of correctly recalled words in learning trials and (2) delayed recall; and for the Logical Memory subtest, Story A (3) immediate recall and (4) delayed recall. Control variables included in the hierarchical linear regressions were age, sex, number of years of education, and time with oxygen saturation <90% during sleep. They were selected because of their possible association with performance on episodic memory tasks (Rönnlund et al., 2005; Morrell and Twigg, 2006). Control variables (age, sex, education, and oxygen desaturation during sleep) and independent variables were all mean centered for regression analyses. Control variables were entered in the analysis in step 1. BDNF polymorphism and sleep variables were entered in step 2, while the interaction
between BDNF polymorphism and sleep variables was entered in step 3. Four hierarchical linear regressions were performed for each sleep variable, namely, NREM SWA and the sleep consolidation index. Correlations among the continuous predictor variables of the study (age, education, time with oxygen saturation <90%, NREM SWA power, and sleep consolidation index) were examined and showed no to moderate correlations, ranging from $r = -0.02$, $p = \text{n.s.}$ to $r = -0.24$, $p < 0.05$. These low $r$ values indicate that multi-collinearity was unlikely. The Bonferroni correction was applied for these eight models, and significance was set at $p < 0.00625$. Outliers were defined by standardized residuals ($z$ scores) of $>3.29$ or $<3.29$ (Tabachnick and Fidell, 2001), and, therefore, data from one Val/Val individual were excluded from one hierarchical regression. Significant interactions were tested using procedures previously described (Aiken and West, 1991), and fitted regression lines were plotted for each level of the dichotomous moderator (i.e., BDNF polymorphism) with an adjusted individual data point.

Control analyses were performed using hierarchical linear regressions with total sleep time as an independent variable to verify whether BDNF polymorphism moderates the association between sleep duration and next-morning learning ability. To verify whether the moderating effect of BDNF polymorphism on sleep was specific to declarative episodic memory, we performed additional hierarchical linear regression analyses on the other neuropsychological tests administered.

**Results**

**No effect of BDNF polymorphism on demographic, neuroimaging, sleep, and neuropsychological variables**

No between-group differences were observed for age, sex ratio, education level, body mass index, hippocampal volume, proportion of subjects carrying the APOE4, and vascular burden index (Table 1). Our sample consisted mainly of men (78.4% of Val/Val carriers and 75% of Met carriers). Using questionnaires, we found no group difference with respect to depression, anxiety, sleep quality, and memory and cognitive complaints. Groups were not different in terms of PSG variables, including respiratory variables (Table 2). Finally, we found no significant group difference on cognitive screening tests, on the episodic memory variables used in the study (Table 3), and on other neuropsychological variables (i.e., Continuous Performance Test, Digit Span, verbal fluency, Color-Word Interference, and Tower of London).

**Moderating effect of BDNF polymorphism on the association between sleep consolidation and memory**

Hierarchical regression models showed that sleep interacts with BDNF polymorphism on both verbal memory tests (Table 4). In fact, BDNF polymorphism was found to have a significant moderating effect on the association between the sleep consolidation index and three of the four memory variables tested (RAVLT learning trials: $\beta = -0.255$, $p < 0.006$; RAVLT delayed recall: $\beta = -0.258$, $p < 0.006$; Logical Memory immediate recall: $\beta = -0.371$, $p < 0.006$; and a trend for Logical Memory delayed recall: $\beta = -0.257$, $p = 0.0074$, which was only a trend for significance when the Bonferroni correction was applied). These
moderating effects explained from 6.3% to 18.1% of the variance on the RAVLT and the Logical Memory subtest. A decomposition of significant interactions showed that, among Val/Val carriers, a higher sleep consolidation index was associated with better memory performance (RAVLT learning trials: $\beta = 0.290$, $p = 0.01$; RAVLT delayed recall: $\beta = 0.306$, $p = 0.006$; Logical Memory immediate recall: $\beta = 0.434$, $p = 0.0001$; Logical Memory delayed recall: $\beta = 0.315$, $p = 0.01$) and accounted for 7.4% to 16.5% of the variance. The significant interaction stemmed from the fact that these positive associations between sleep consolidation and memory performance were not observed among Met carriers. In fact, better sleep consolidation was associated with poorer memory performance on Logical Memory immediate recall ($\beta = -0.585$, $p = 0.005$; Fig. 1A) and explained 28.7% of the variance. Trends for negative associations were also found between sleep consolidation and performance on RAVLT learning trials ($\beta = -0.352$, $p = 0.07$; Fig. 1B) and Logical Memory delayed recall ($\beta = -0.392$, $p = 0.056$).

No moderating effect of $BDNF$ polymorphism on NREM SWA and total sleep time

NREM SWA was not associated with memory performance the next morning. Moreover, no significant interaction between $BDNF$ polymorphism and NREM SWA power was observed. Analyses were conducted with total sleep time as an independent variable; no significant interaction with $BDNF$ polymorphism was found to predict memory performance, although trends for significant effects were observed for RAVLT delayed recall ($\beta = 0.216$, $p = 0.03$) and Logical memory immediate recall ($\beta = 0.174$, $p = 0.08$). Independent of $BDNF$ polymorphism, longer sleep duration was associated with better performance on both RAVLT and Logical Memory immediate recalls ($\beta$-values of 0.233 and 0.249, respectively; $p = 0.01$).

Cognitive domains other than memory

Supplementary analyses with other neuropsychological tests revealed that the $BDNF$ Met allele selectively compromises the association between sleep and verbal memory with little effect on tasks involving the prefrontal cortex and no impact on other cognitive domains. Although trends for sleep (NREM SWA or sleep consolidation index) by $BDNF$ polymorphism interaction were found for Digit Span, Trail Making Test part B, and Color-Word Interference (time to complete Condition 3; $p$ values <0.05, but >0.01), no significant interaction persisted when a correction for multiple testing was applied.

Discussion

Sleep consolidation and NREM SWA have been identified as having a crucial role in learning (Tartar et al., 2006; Yoo et al., 2007; Van Der Werf et al., 2009; Rolls et al., 2011; Wallace et al., 2015). In the present study, we observed that $BDNF$ Val/Met polymorphism moderates the association between memory and the sleep consolidation index, a variable integrating the number of awakenings, sleep efficiency, and the longest sleep bout. More specifically, we found that a night of consolidated sleep was associated with better learning abilities the next morning among Val/Val carriers. Our results confirm previous animal models showing the specific effect of sleep fragmentation on memory (Tartar et al., 2006; Rolls et al., 2011; Wallace et al., 2015). However, this positive sleep–memory association...
was not observed among Met carriers. These results support the hypothesis that reduced activity-dependent secretion of BDNF impairs the benefits of sleep on synaptic plasticity and next-day memory.

**Lower sleep consolidation is associated with better learning among Met carriers**

Interestingly, for Logical Memory immediate recall in Met carriers, we observed that lower sleep consolidation was associated with better learning. This negative association was also found for the three other memory variables in Met carriers, but failed to reach significance (p value range from 0.056 to 0.15). This raises the question as to whether Met carriers see a benefit from increased sleep fragmentation (i.e., the number of awakenings during the night) in the form of improvements in their next-day memory performance. One explanation may be the use of an efficient compensatory cognitive strategy among Met carriers who experienced a poor night of sleep. In a rodent study, it was observed that sleep-deprived mice avoided the use of a hippocampus-dependent strategy to perform a memory task and instead used a striatum-dependent strategy (Hagewoud et al., 2010). In parallel, previous studies in elderly subjects have shown that Met carriers have more efficient or preserved frontostriatal functions than Val/Val individuals (Gajewski et al., 2012; Getzmann et al., 2013). Although declarative memory was believed to mostly depend on hippocampus integrity, there is now compelling evidence that the striatum, along with the prefrontal cortex, may be involved (Scimeca and Badre, 2012). Our findings thus raise the intriguing possibility that poor sleep consolidation may have promoted the use of a striatum-dependent memory strategy that is potentially advantageous to Met carriers, who may have more efficient or better preserved frontostriatal functions than Val/Val individuals.

Another explanation might reside in a possible enhancement of BDNF expression during nighttime wakefulness. Indeed, BDNF mRNA expression has been reported to increase with acute prolonged wakefulness in rodents (Huber et al., 2007; El Helou et al., 2013). This increased BDNF expression may benefit next-day memory in the Met carriers who experienced frequent awakenings during their night of sleep. The negative association between sleep consolidation and memory was not observed among Val homozygotes, possibly because they already have abundant levels of BDNF. According to this hypothesis, a consolidated sleep will have more benefits in improving memory in Val/Val carriers, compared with Met allele carriers, because of their abundant levels of BDNF.

**BDNF polymorphism is not a moderator of NREM SWA and memory association in middle-aged and older individuals**

Surprisingly, there was a lack of interaction between BDNF polymorphism and NREM SWA, suggesting that SWA plays the same role in next-day learning ability among Val/Val and Met carriers. However, we cannot exclude the idea that the lack of moderating effect may stem from our sample, which was made up of individuals between 55 and 84 years of age, a segment of the population known to experience less slow-wave sleep than younger adults (Carrier et al., 2001). In parallel, it was reported that Val/Val carriers had more slow-wave sleep and more SWA than Met carriers (Bachmann et al., 2012), but another study failed to observe a group difference in their sleep characteristics (Mascetti et al., 2013). In rodents, BDNF injection over the hippocampus was also shown to increase SWA (Faraguna
et al., 2008). However, in the present study, we found that BDNF polymorphism had no effect on SWA. Again, this lack of a BDNF polymorphism group difference may be attributable to the fact that our participants were middle-aged or older adults.

The moderating effect of BDNF polymorphism is stronger for memory than for other cognitive functions

The moderating role of BDNF polymorphism in sleep consolidation was specific to episodic memory tasks. Although trends for significant moderating effects were found for tests mostly involving the prefrontal cortex, no significant interaction was observed for the other cognitive domains, reflecting that sleep by BDNF polymorphism interaction is more salient for hippocampus-dependent tasks than for other cognitive tasks. Concordant with this observation, a previous study of sleep deprivation failed to find a sleep by BDNF polymorphism interaction to explain working memory performance in young adults (Bachmann et al., 2012). Another study showed that Val/Val carriers have a greater increase in their performance in memorizing neutral faces learned before sleep than Met carriers, demonstrating that BDNF polymorphism interacts with sleep to explain overnight memory consolidation for a hippocampus-dependent task (Mascetti et al., 2013).

Sleep quality is a key element to understanding the effect of BDNF polymorphism on episodic memory

Our results explain some of the inconsistencies observed regarding the better performance of Val/Val carriers over Met carriers for episodic memory (Mandelman and Grigorenko, 2012). In fact, we showed that the enhanced performance of Val/Val carriers was observed only when subjects experienced a night of well consolidated sleep before learning. Thus, uncontrolled sleep quality preceding memory testing in previous studies may have led to heterogeneous results for the effect of BDNF polymorphism on episodic memory. The significant interaction between sleep consolidation and BDNF polymorphism may be an essential missing variable, particularly in middle-aged and older populations.

Strengths and limitations of the study

The strengths and limitations of this study relate mainly to the characteristics of our sample. The BDNF polymorphism groups were not different for all demographic variables (including education), subjective cognitive complaints, vascular burden, neuro-psychological performance, hippocampal volume, and APOE4 genotype. We can therefore assume that the groups were similar with respect to the proportion of individuals with preclinical dementia. Nonetheless, we cannot exclude the fact that some individuals might have been in a presymptomatic stage of dementia, and biomarkers such as positron emission tomography with the Pittsburgh Compound-B ligand would have been of great interest in our sample (Jack et al., 2016). Whether the neural consequences of chronic sleep fragmentation predict a further cognitive decline among older individuals is an interesting question that needs to be investigated with longitudinal studies that carefully track sleep history.

Our sample consisted mainly of men. Although sex was added as a control variable in our statistics, we should be cautious in extending the present findings to women. Another factor to consider is that 31% of our subjects were recruited from the waiting list for a sleep apnea
clinic, which means our sample included a higher proportion of individuals with sleep apnea (47.7% of our sample) than the 17% expected prevalence for men 50–70 years of age (Peppard et al., 2013). To control for the effect of obstructive sleep apnea, we included time spent with oxygen saturation <90% during sleep as a control variable in the regression analyses. Another limitation is the sample size of the Met carrier group, which was smaller than the Val/Val group. This lower proportion was nevertheless expected, given the frequency of the Met allele in the population (Egan et al., 2003). However, in the case of significant interactions, we reported $R^2$ changes, which represent effect size and allow us to compare the associations observed for each group. Finally, the results of this study must be replicated with an independent sample, and a comparison of young versus older adults is the next step to understanding how BDNF polymorphism moderates the sleep–memory association.

Conclusions

Our work advances the field by revealing new evidence of genetic heterogeneity in how sleep consolidation contributes to learning ability. It reveals a complex, intricate relationship among sleep, BDNF polymorphism, and learning that merits further attention. This study confirms that better sleep consolidation is associated with better next-day learning in Val/Val individuals, who account for most of the population. However, our results also stress the importance of considering BDNF polymorphism when studying how sleep affects cognition, since the positive effect of sleep consolidation on memory was not found in Met carriers. Understanding the effect of the BDNF Met allele on specific components of a simple form of learning provides insight into the consequences of specific sleep disorders, particularly medical or neurodegenerative conditions that cause sleep fragmentation and memory dysfunction, such as obstructive sleep apnea (Gagnon et al., 2014) and Alzheimer’s disease (Widner et al., 2000). It is worth looking into whether sleep disorders have the same long-term detrimental effects on brain health and cognition in BDNF Val/Val and Met carriers.

Acknowledgments

This work was supported by the Canadian Institutes of Health Research (operating grants to N.G., J.M., J.-F.G., L.D.B., and J.P., a salary award to J.-F.G., and a studentship award to A.-A.B.) and by the Fonds de recherche du Québec–Santé (salary awards to N.G., L.D.B., V.M., J.-F.G., S.P., and J.C.). J.-F.G. holds the Canadian Research Chair in Cognitive Decline in Pathological Aging, while J.M. holds the Canadian Research Chair on Sleep Medicine. We thank Gaétan Poirier, Dr. Jean Paquet, Caroline D’Aragon, Danièle Legault, Marie-Josée Quinn, Dr. Marjolaine Lafortune, Nazmiye Uzun, Dr. Catherine Chapados-Noreau, Dr. Frédérique Escudier, and the staff of the Center for Advanced Research in Sleep Medicine of Hôpital du Sacré-Cœur de Montréal for their contribution to subject testing and data analysis. We also thank Louise Thérioux and Mélanie Wellman for their contribution to genotyping analyses.

References


J Neurosci. Author manuscript; available in PMC 2018 February 13.


Rey A. L’examen psychologique dans les cas d’encéphalopathie traumatique. Arch Psychol. 1941; 28:286.


Van Der Werf YD, Altena E, Vis JC, Koene T, Van Someren EJ. Reduction of nocturnal slow-wave activity affects daytime vigilance lapses and memory encoding but not reaction time or implicit learning. Prog Brain Res. 2011; 193:245–255. [PubMed: 21854967]


Significance Statement

Individuals with the BDNF Val/Val (valine allele) polymorphism showed better memory performance after a night of consolidated sleep. However, we observed that middle-aged and older individuals who are carriers of the BDNF Met allele displayed no positive association between sleep quality and their ability to learn the next morning. This interaction between sleep and BDNF polymorphism was more salient for hippocampus-dependent tasks than for other cognitive tasks. Our results support the hypothesis that reduced activity-dependent secretion of BDNF impairs the benefits of sleep on synaptic plasticity and next-day memory. Our work advances the field by revealing new evidence of a clear genetic heterogeneity in how sleep consolidation contributes to the ability to learn.
Figure 1.
Sleep consolidation and memory performance for Val/Val and Met carriers. A, B. Fitted regression lines for Logical Memory: Story A immediate recall (A) and Rey Auditory Verbal Learning Test learning trials (B) according to sleep consolidation index in Val/Val (open gray circles) and Met carriers (black triangles). A higher sleep consolidation index represents a more consolidated sleep. Individual data points represent values adjusted for control variables (age, sex, education, time with oxygen saturation <90% during sleep).
Table 1

Characteristics of Val/Val and Met carriers

<table>
<thead>
<tr>
<th>Variables</th>
<th>Val/Val carriers (n = 79)</th>
<th>Met carriers (n = 28)</th>
<th>$t$/$\chi^2$ values</th>
<th>$p$ values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63.5 ± 6.3</td>
<td>63.2 ± 6.5</td>
<td>0.2</td>
<td>n.s.</td>
</tr>
<tr>
<td>Male sex (%)</td>
<td>78.4</td>
<td>75</td>
<td>0.14</td>
<td>n.s.</td>
</tr>
<tr>
<td>Education (years)</td>
<td>15.8 ± 4.0</td>
<td>14.5 ± 2.8</td>
<td>1.8</td>
<td>n.s.</td>
</tr>
<tr>
<td>Body mass index (kg/m$^2$)</td>
<td>27.0 ± 6.0</td>
<td>27.7 ± 3.9</td>
<td>−0.5</td>
<td>n.s.</td>
</tr>
<tr>
<td>Vascular Burden Index</td>
<td>1.3 ± 1.3</td>
<td>1.5 ± 1.3</td>
<td>−0.7</td>
<td>n.s.</td>
</tr>
<tr>
<td>Beck Depression Inventory</td>
<td>7.2 ± 5.3</td>
<td>5.9 ± 6.6</td>
<td>1.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Beck Anxiety Inventory</td>
<td>4.6 ± 4.4</td>
<td>4.2 ± 4.8</td>
<td>0.4</td>
<td>n.s.</td>
</tr>
<tr>
<td>Pittsburgh Sleep Quality Index</td>
<td>5.0 ± 3.2</td>
<td>5.7 ± 3.7</td>
<td>−1.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Epworth Sleepiness Scale</td>
<td>7.9 ± 4.7</td>
<td>9.0 ± 6.0</td>
<td>−1.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Insomnia Severity Index</td>
<td>7.0 ± 5.2</td>
<td>8.5 ± 5.8</td>
<td>−1.2</td>
<td>n.s.</td>
</tr>
<tr>
<td>Self-evaluation Questionnaire</td>
<td>1.5 ± 1.0</td>
<td>1.7 ± 1.0</td>
<td>−0.5</td>
<td>n.s.</td>
</tr>
<tr>
<td>Cognitive Failure Questionnaire</td>
<td>27.8 ± 12.2</td>
<td>30.0 ± 13.7</td>
<td>−0.8</td>
<td>n.s.</td>
</tr>
<tr>
<td>Right hippocampal volume (mm$^3$)</td>
<td>3924.2 ± 456.1</td>
<td>4061.8 ± 413.1</td>
<td>−1.1</td>
<td>n.s.</td>
</tr>
<tr>
<td>Left hippocampal volume (mm$^3$)</td>
<td>3736.2 ± 442.3</td>
<td>3890.9 ± 351.0</td>
<td>−1.4</td>
<td>n.s.</td>
</tr>
<tr>
<td>APOE (% with ε4)</td>
<td>15</td>
<td>25</td>
<td>1.36</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

Values are reported as the mean ± SD, unless otherwise indicated. n.s., not significant.
Table 2

<table>
<thead>
<tr>
<th>Variables</th>
<th>Val/Val carriers (n = 79)</th>
<th>Met carriers (n = 28)</th>
<th>t values</th>
<th>p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage N1 sleep (min)</td>
<td>81.4 ± 33.7</td>
<td>82.1 ± 41.7</td>
<td>−0.1</td>
<td>n.s.</td>
</tr>
<tr>
<td>Stage N2 sleep (min)</td>
<td>196.2 ± 53.1</td>
<td>192.8 ± 64.2</td>
<td>0.3</td>
<td>n.s.</td>
</tr>
<tr>
<td>Stage N3 sleep (min)</td>
<td>23.0 ± 26.2</td>
<td>31.6 ± 29.7</td>
<td>−1.4</td>
<td>n.s.</td>
</tr>
<tr>
<td>REM sleep (min)</td>
<td>53.5 ± 24.3</td>
<td>49.9 ± 23.0</td>
<td>0.7</td>
<td>n.s.</td>
</tr>
<tr>
<td>Total sleep time (min)</td>
<td>354.1 ± 66.6</td>
<td>356.3 ± 77.5</td>
<td>−0.2</td>
<td>n.s.</td>
</tr>
<tr>
<td>Number of awakenings</td>
<td>47.9 ± 20.1</td>
<td>45.3 ± 26.0</td>
<td>0.6</td>
<td>n.s.</td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td>76.8 ± 12.1</td>
<td>76.9 ± 13.0</td>
<td>−0.02</td>
<td>n.s.</td>
</tr>
<tr>
<td>Longest sleep bout (min)</td>
<td>55.8 ± 18.1</td>
<td>56.6 ± 20.9</td>
<td>−0.2</td>
<td>n.s.</td>
</tr>
<tr>
<td>Slow-wave activity power (μV²/30 s)</td>
<td>222.9 ± 112.1</td>
<td>260.0 ± 158.1</td>
<td>−1.3</td>
<td>n.s.</td>
</tr>
<tr>
<td>Apnea–hypopnea index</td>
<td>20.3 ± 17.1</td>
<td>18.9 ± 15.1</td>
<td>0.4</td>
<td>n.s.</td>
</tr>
<tr>
<td>Time with oxygen saturation &lt;90% (min)</td>
<td>7.1 ± 15.2</td>
<td>13.3 ± 22.7</td>
<td>−1.6</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

Values are reported as the mean ± SD. n.s., not significant.
### Table 3

Neuropsychological results for Val/Val and Met carriers

<table>
<thead>
<tr>
<th>Variables</th>
<th>Val/Val carriers (n = 79)</th>
<th>Met carriers (n = 28)</th>
<th>t values</th>
<th>p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>MoCA</td>
<td>27.8 ± 2.1</td>
<td>27.0 ± 2.2</td>
<td>1.7</td>
<td>n.s.</td>
</tr>
<tr>
<td>MMSE</td>
<td>28.7 ± 1.4</td>
<td>29.0 ± 0.9</td>
<td>−1.3</td>
<td>n.s.</td>
</tr>
<tr>
<td>RAVLT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Learning trials (no. of words)</td>
<td>49.1 ± 10.2</td>
<td>47.1 ± 9.1</td>
<td>0.9</td>
<td>n.s.</td>
</tr>
<tr>
<td>Delayed recall (no. of words)</td>
<td>9.5 ± 3.3</td>
<td>9.6 ± 3.1</td>
<td>0.02</td>
<td>n.s.</td>
</tr>
<tr>
<td>Logical Memory subtest of WMS-III</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Story A immediate recall</td>
<td>14.3 ± 3.8</td>
<td>14.7 ± 3.6</td>
<td>−0.5</td>
<td>n.s.</td>
</tr>
<tr>
<td>Story A delayed recall</td>
<td>16.6 ± 3.5</td>
<td>17.6 ± 2.4</td>
<td>−1.4</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

Values are reported as the mean ± SD. MoCA, Montreal Cognitive Assessment; MMSE, Mini Mental State Examination; WMS-III, Wechsler Memory Scale, third edition; n.s., not significant.
Table 4

Hierarchical regression analyses with BDNF polymorphism and sleep consolidation index predicting scores on RAVLT and Logical Memory immediate and delayed recalls

<table>
<thead>
<tr>
<th>Predictors</th>
<th>RAVLT</th>
<th>Logical Memory</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>R² change</td>
</tr>
<tr>
<td>Learning trials (RAVLT)/immediate recall (Logical Memory)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Step 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.162</td>
<td>19.0% **</td>
</tr>
<tr>
<td>Sex</td>
<td>0.363</td>
<td>0.237 *</td>
</tr>
<tr>
<td>Education</td>
<td>0.234</td>
<td>0.291</td>
</tr>
<tr>
<td>Oxygen saturation &lt;90% during sleep</td>
<td>0.029</td>
<td></td>
</tr>
<tr>
<td>Step 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDNF polymorphism group</td>
<td>−0.084</td>
<td>20.7% **</td>
</tr>
<tr>
<td>Sleep consolidation index</td>
<td>0.113</td>
<td>0.064</td>
</tr>
<tr>
<td>Step 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDNF polymorphism group × sleep consolidation index</td>
<td>−0.255</td>
<td>27.0% **</td>
</tr>
<tr>
<td>Delayed recalls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Step 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>−0.079</td>
<td>14.6% **</td>
</tr>
<tr>
<td>Sex</td>
<td>0.312</td>
<td>0.125</td>
</tr>
<tr>
<td>Education</td>
<td>0.242</td>
<td>0.207 *</td>
</tr>
<tr>
<td>Oxygen saturation &lt;90% during sleep</td>
<td>0.131</td>
<td>0.099</td>
</tr>
<tr>
<td>Step 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDNF polymorphism group</td>
<td>−0.002</td>
<td>15.9% *</td>
</tr>
<tr>
<td>Sleep consolidation index</td>
<td>0.121</td>
<td>0.134</td>
</tr>
<tr>
<td>Step 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDNF polymorphism group × sleep consolidation index</td>
<td>−0.258</td>
<td>22.3% **</td>
</tr>
</tbody>
</table>

*p < 0.05 (trend for significance),

**p < 0.00625 (p level threshold when Bonferroni correction was applied).